

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: UCSD-07017

Serial No.: 09/788,110

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Maurizio Zanetti

Filing Date: 02/15/01

Group Art Unit:

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
SM	1	4,622,952	11/18/86	Gordon			
	2	5,658,234	8/19/97	Dunlavy			
	3	6,106,829	8/22/00	He <i>et al.</i>			
	4	6,168,946	1/2/01	Houghton <i>et al.</i>			
	5	5,635,188	6/3/97	Bystryn			

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

SM	6	Mattes <i>et al.</i> (1983) "A Pigmentation-associated, Differentiation Antigen of Human Melanoma Defined by a Precipitating Antibody in Human Serum," <i>Int. J. Cancer</i> 32:717
	7	Tai <i>et al.</i> (1983) "Glycoproteins as Differentiation Markers in Human Malignant Melanoma and Melanocytes," <i>Cancer Res.</i> 43:2773
	8	Thomson <i>et al.</i> (1988) "Differentiation Antigens of Melanocytes and Melanoma: Analysis of Melanosome and Cell Surface Markers of Human Pigmented Cells with Monoclonal Antibodies," <i>J. Invest. Dermatol.</i> 90:459
	9	Zakian (1995) "Telomeres: Beginning to Understand the End," <i>Science</i> 270:1601
	10	Blackburn and Gall (1978) "A Tandemly Repeated Sequence at the Termini of the Extrachromosomal Ribosomal RNA Genes in <i>Tetrahymena</i> ," <i>J. Mol. Biol.</i> 120:33
	11	Oka <i>et al.</i> (1980) "Inverted terminal repeat sequence in the macronuclear DNA of <i>Stylonychia pustulata</i> ," <i>Gene</i> 10:301
	12	Klobutcher <i>et al.</i> (1981) "All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3' terminus," <i>Proc. Natl. Acad. Sci.</i> 78:3015
	13	Wellinger <i>et al.</i> (1993) "Origin Activation and Formation of Single-Strand TG _n Tails Occur Sequentially in Late S Phase on a Yeast Linear Plasmid," <i>Mol. Cell. Biol.</i> 13:4057
	14	Minev <i>et al.</i> (2000) "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans," <i>Proc. Natl. Acad. Sci. USA</i> 97:4796-4801
	15	Vonderheide <i>et al.</i> (1999) "The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes," <i>Immunity</i> 10:673-679
	16	Blackburn (1992) "Telomerases," <i>Ann. Rev. Biochem.</i> 61:1139-129
	17	Blackburn (1991) "Structure and function of telomeres," <i>Nature</i> 350:569-73
	18	Greider (1994) "Mammalian telomere dynamics: healing, fragmentation shortening and stabilization," <i>Curr. Opin. Genet. Devel.</i> 4:203-11
	19	Counter <i>et al.</i> (1992) "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity," <i>EMBO J.</i> 11:1921-29
	20	Buchkovich <i>et al.</i> (1996) "Telomerase Regulation during Entry into the Cell Cycle in Normal Human T Cells," <i>Mol. Biol. Cell</i> 7:1443-54
	21	Weng <i>et al.</i> (1996) "Regulated Expression of Telomerase Activity in Human T Lymphocyte Development and Activation," <i>J. Exp. Med.</i> 183:2471-9
	22	Weng <i>et al.</i> (1997) "Telomere lengthening and telomerase activation during human B cell differentiation," <i>Proc. Natl. Acad. Sci. USA</i> 94:10827-32
	23	Lee <i>et al.</i> (1998) "Essential role of mouse telomerase in highly proliferative organs," <i>Nature</i> 392:569-74
	24	Kim <i>et al.</i> (1994) "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," <i>Science</i> 266:2011-5
	25	Meyerson <i>et al.</i> (1997) "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, is Up-Regulated in Tumor Cells and during Immortalization," <i>Cell</i> 90:785-795

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UCSD-02424		Serial No.: 08/723,052	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Mario Chojkier <i>et al.</i>			
				Filing Date: 09/30/96		Group Art Unit:	
(37 CFR § 1.98(b))							
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)							
26	Bodnar <i>et al.</i> (1998) "Extension of Life-Span by Introduction of Telomerase into Normal Human Cells," <i>Science</i> 279:349-52	<div style="position: absolute; top: 0; right: 0; text-align: right;"> RECEIVED DEC 03 2002 TECH CENTER 1000/2000 </div>					
27	Rudolph <i>et al.</i> (1999) "Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice," <i>Cell</i> 96:701-12						
28	Greenberg <i>et al.</i> (1999) "Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4a ^{+/+} Cancer-Prone Mouse," <i>Cell</i> 97:515-25						
28	Morales <i>et al.</i> (1999) "Absence of cancer-associated changes in human fibroblasts immortalized with telomerase," <i>Nature Genetics</i> 21:115-8						
30	Hahn <i>et al.</i> (1999) "Creation of human tumour cells with defined genetic elements," <i>Nature</i> 400:464-8						
31	Broccoli <i>et al.</i> (1995) "Telomerase activity in normal and malignant hematopoietic cells," <i>Proc. Natl. Acad. Sci. USA</i> 92:9989-9						
32	Shay <i>et al.</i> (1997) "A Survey of Telomerase Activity in Human Cancer," <i>Eur. J. Cancer</i> 33:787-91						
33	Kim (1997) "Clinical Implications of Telomerase in Cancer," <i>Eur. J. Cancer</i> 33:781-6						
34	Nakamura <i>et al.</i> (1997) "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human," <i>Science</i> 277:955-9						
35	Marx (1993) "How p53 Suppresses Cell Growth," <i>Science</i> 262:1644-5						
36	Disis <i>et al.</i> (1997) "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer," <i>Adv. Cancer Res.</i> 71:343-71						
37	Walker <i>et al.</i> (1988) "HIV-1 Reverse Transcriptase Is a Target for Cytotoxic T Lymphocytes in Infected Individuals," <i>Science</i> 240:64-6						
38	Schwartz (1990) "A Cell Culture Model for T Lymphocyte Clonal Anergy," <i>Science</i> 248:1349-56						
39	Firat <i>et al.</i> (1999) "H-2 class I knockout, HLA-12.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies," <i>Eur. J. Immunol.</i> 29:3112-21						
40	Lee (1990) in <i>The HLA System</i> , ed. Lee, J. (Springer-Verlag, NY), pp 141-178						
41	Fernandez-Vina <i>et al.</i> (1992) "DNA Typing for HLA Class I Alleles. I. Subsets of HLA-A2 and of -A28," <i>Human Immunol.</i> 33:163-73						
42	Krausa <i>et al.</i> (1995) "Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations," <i>Tissue Antigens</i> 45:223-31;						
43	Ruppert <i>et al.</i> (1993) "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," <i>Cell</i> 74:929-37;						
44	Parker <i>et al.</i> (1994) "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>J. Immunol.</i> 152:163-75						
45	Vitiello <i>et al.</i> (1991) "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," <i>J. Exp. Med.</i> 173:1007-15						
46	Sette <i>et al.</i> (1994) "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," <i>J. Immunol.</i> 153:5586-92						
47	van der Burg <i>et al.</i> (1996) "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability," <i>J. Immunol.</i> 156:3308-14						
48	Sommerfeld <i>et al.</i> (1996) "Telomerase Activity: A Prevalent Marker of Malignant Human Prostate Tissue," <i>Cancer Res.</i> 56:218-22						
49	Hunt <i>et al.</i> (1992) "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 1261-3						
50	Quaranta <i>et al.</i> (1982) "A Recurrent Idiotype on Monoclonal Anti-Human Ia Antibodies," <i>J. Exp. Med.</i> 156:1551-6						
51	Zanetti <i>et al.</i> (1993) "Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif," <i>EMBO J.</i> 12:4375-4384						
52	Hiyama <i>et al.</i> (1995) "Activation of Telomerase in Human Lymphocytes and Hematopoietic Progenitor Cells," <i>J. Immunol.</i> 155:3711-15						
53	Pascolo <i>et al.</i> (1997) "HLA-A2.1-restricted Education and Cytolytic Activity of CD8 ⁺ T Lymphocytes from β 2 Microglobulin (β 2m) HLA-A2.1 Monochain Transgenic H-2D ^b β 2m Double Knockout Mice," <i>J. Exp. Med.</i> 185:2043-51						
54	Doyle <i>et al.</i> (1985) "Markedly Decreased Expression of Class I Histocompatibility Antigens, Protein, and mRNA in Human Small-Cell Lung Cancer," <i>J. Exp. Med.</i> 161:1135-51						
Examiner: <i>J. Gye</i>				Date Considered: <i>8/23/04</i>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UCSD-02424		Serial No.: 08/723,052	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Mario Chojkier <i>et al.</i>			
				Filing Date: 09/30/96		Group Art Unit:	
(37 CFR § 1.98(b))							
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)							
55	/	Momburg <i>et al.</i> (1986) "Loss of HLA-A,B,C and <i>De Novo</i> Expression of HLA-D in Colorectal Cancer," Int. J. Cancer 37:179-84	<div style="text-align: center;"> RECEIVED DEC 03 2002 TECH CENTER 1800/2900 </div>				
56	/	Restifo <i>et al.</i> (1993) "Identification of Human Cancers Deficient in Antigen Processing," J. Exp. Med. 177:165-7					
57	/	Cromme <i>et al.</i> (1994) "Loss of Transporter Protein, Encoded by the TAP-1 Gene, is Highly Correlated with Loss of HLA-A Expression in Cervical Carcinomas," J. Exp. Med. 179:335-40					
58	/	Rosenberg <i>et al.</i> (1998) "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with melanoma," Nature Med. 4:321-27					
59	/	Nestle <i>et al.</i> (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," Nature Med. 4:328-332					
60	/	Thomson <i>et al.</i> (1998) "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," J. Immunol. 160:1717-23					
61	/	Sykulev <i>et al.</i> (1996) "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response," Immunity 4:565-71					
62	/	Morgan <i>et al.</i> (1998) "Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity," J. Immunol. 160:643-51					
63	/	Overwijk <i>et al.</i> (1999) "Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4 ⁺ T lymphocytes," Proc. Natl. Acad. Sci. USA 96:2982-7					
64	/	Hu <i>et al.</i> (1993) "An Evaluation of the Potential to Use Tumor-associated Antigens as Targets for Antitumor T Cell Therapy Using Transgenic Mice Expressing a Retroviral Tumor Antigen in Normal Lymphoid Tissues," J. Exp. Med. 177:1681-90					
65	/	Uyttenhove <i>et al.</i> (1997) "The Expression of Mouse Gene <i>PIA</i> In Testis Does Not Prevent Safe Induction of Cytolytic T Cells Against a <i>PIA</i> -Encoded Tumor Antigen," Int. J. Cancer 70:349-56					
66	/	Falk <i>et al.</i> (1991) "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature 351:290-6					
67	/	Rotzschke <i>et al.</i> (1990) "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," Nature 348:252-254					
68	/	Schumacher <i>et al.</i> (1991) "Peptide selection by MHC class I molecules," Nature 350:703-6					
Examiner:		<i>[Signature]</i>		Date Considered:		8/23/04	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

